Clinical Trial

Disease: Solid tumors, (NCT05395052)

Disease info:

A solid tumour is an abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumours may be benign (not cancer), or malignant (cancer). Solid tumour types are named according to the type of cell they originate from. Examples of solid tumours are sarcomas, carcinomas, and lymphomas. Leukaemias (cancers of the blood) generally do not form solid tumours. 

Frequency:
Based on projections, cancer deaths will continue to rise with an estimated 11.4 million cancer-related deaths per year in 2030.
Official title:
A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
Who:

Contact: Lilian Liu,  858-875-1800,  clinical@fatetherapeutics.com
Contact: Karen Albers,  858-875-1800,   clinical@fatetherapeutics.com

Partners:

-

Locations:

United States, North Carolina

Study start:
May. 31, 2022
Enrollment:
322
Gene editing method:
CRISPR
Type of edit:
Gene knock-out
Gene:
CD38
Delivery method:
Undisclosed - Ex-vivo
Indicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Active recruiting

Description

This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in subjects with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Last updated: Jul. 28, 2022
close
Search CRISPR Medicine